Literature DB >> 10849026

Metabolic and inflammatory responses to pulmonary exacerbation in adults with cystic fibrosis.

S C Bell1, A M Bowerman, L E Nixon, I A Macdonald, J S Elborn, D J Shale.   

Abstract

BACKGROUND: We hypothesized that increased resting energy expenditure in adults with cystic fibrosis was related to chronic inflammation secondary to pulmonary infection and could be modified by treatment of the underlying infection.
METHOD: To determine the relationship between resting energy expenditure and the inflammatory and metabolic responses, we studied 22 adults with cystic fibrosis and chronic Pseudomonas aeruginosa infection before and after treatment of a respiratory exacerbation. Resting energy expenditure was measured by indirect calorimetry. Spirometry and circulating concentrations of C-reactive protein, neutrophil elastase alpha1-antiproteinase complex, catecholamines, non-esterified fatty acids and glycerol were determined.
RESULTS: The mean (95% confidence interval)% predicted FEV1 was 28.5% (20.6, 36.4) and mean body weight 50.7 kg (47.4, 54.1). Following treatment, 1-s forced expiratory volume (FEV1) and weight increased, while C-reactive protein (P<0.0001) and neutrophil elastase alpha1-antiproteinase complex concentrations (P<0.0001) were reduced. Resting energy expenditure decreased from 6.8 (6.3, 7.2) to 6.25 (5.9, 6.6) MJ day-1 by day 15 (P<0.001). Changes in resting energy expenditure and C-reactive protein were related (r = 0.66, P< 0.0001). Weight gain was inversely related to resting energy expenditure (r = 0.43, P = 0.02) and unrelated to energy intake (r = 0.02, P = 0.47). Post-treatment reduction in norepinephrine was related to changes in heart rate (r = 0.57, P<0.01), resting energy expenditure (r = 0.51, P = 0.001) and non-esterified fatty acids (r = 0.42, P< 0.05).
CONCLUSIONS: A parallel reduction in the host inflammatory and catabolic responses followed treatment of a respiratory exacerbation and may have contributed to weight gain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10849026     DOI: 10.1046/j.1365-2362.2000.00667.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  15 in total

1.  Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: A pilot randomized study of high-dose vitamin D3 administration.

Authors:  Jessica A Alvarez; Elizabeth Y Chong; Douglas I Walker; Joshua D Chandler; Ellen S Michalski; Ruth E Grossmann; Karan Uppal; Shuzhao Li; Jennifer K Frediani; Rabindra Tirouvanziam; ViLinh T Tran; Vin Tangpricha; Dean P Jones; Thomas R Ziegler
Journal:  Metabolism       Date:  2017-02-11       Impact factor: 8.694

Review 2.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

3.  Prevalence and clinical significance of Staphylococcus aureus small-colony variants in cystic fibrosis lung disease.

Authors:  Silke Besier; Christina Smaczny; Christian von Mallinckrodt; Andreas Krahl; Hanns Ackermann; Volker Brade; Thomas A Wichelhaus
Journal:  J Clin Microbiol       Date:  2006-11-15       Impact factor: 5.948

4.  Investigation of respiratory rate in patients with cystic fibrosis using a minimal-impact biomotion system.

Authors:  Svenja Straßburg; Carolin-Maria Linker; Sebastian Brato; Christoph Schöbel; Christian Taube; Jürgen Götze; Florian Stehling; Sivagurunathan Sutharsan; Matthias Welsner; Gerhard Weinreich
Journal:  BMC Pulm Med       Date:  2022-02-11       Impact factor: 3.317

Review 5.  Novel end points for clinical trials in young children with cystic fibrosis.

Authors:  Shannon J Simpson; Lauren S Mott; Charles R Esther; Stephen M Stick; Graham L Hall
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

6.  Insulin-like growth factor I correlates with lean body mass in cystic fibrosis patients.

Authors:  I Sermet-Gaudelus; J C Souberbielle; I Azhar; J C Ruiz; P Magnine; V Colomb; C Le Bihan; D Folio; G Lenoir
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

7.  Glucose tolerance during pulmonary exacerbations in children with cystic fibrosis.

Authors:  John Widger; Mark R Oliver; Michele O'Connell; Fergus J Cameron; Sarath Ranganathan; Phil J Robinson
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

8.  Severe hypercapnia in critically ill adult cystic fibrosis patients.

Authors:  Hassan S Sheikh; Noel Dexter Tiangco; Christopher Harrell; Robert L Vender
Journal:  J Clin Med Res       Date:  2011-09-26

9.  Impact of exacerbations of cystic fibrosis on muscle strength.

Authors:  Chris Burtin; Hans Van Remoortel; Bart Vrijsen; Daniel Langer; Kristine Colpaert; Rik Gosselink; Marc Decramer; Lieven Dupont; Thierry Troosters
Journal:  Respir Res       Date:  2013-04-19

Review 10.  Home versus hospital intravenous antibiotic therapy for cystic fibrosis.

Authors:  Albert Balaguer; Javier González de Dios
Journal:  Cochrane Database Syst Rev       Date:  2015-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.